Compound ID | 1843
Class: Natural product antibiotic
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | Protein synthesis inhibitor. Stabilises peptidyl-tRNA in the pretranslocation complex, preventing translocation of the ribosome along the mRNA |
| Target Pathogen: | Active against Mycobacterium spp. |
| Description: | Streptomyces natural product; rarely used as alternative for multidrug resistant tuberculosis in combination; administered intravenously or in aerosol form; tuberactinomycin-type antibiotic (cyclic peptide often grouped with aminoglycoside) |
| Year first mentioned: | 1960 |
| Highest development stage: | Approved by FDA in 1971 |
| Development status: | Withdrawn |
| Reason dropped: | Poses health risks such as ear toxicity (ototoxicity), hearing loss, and kidney dysfunction (nephrotoxicity) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/3000502 |
| Guide to Pharmacology: | capreomycin IB |
| Citations: |
|